Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

MCTA vs ACMR vs ICHR vs CANG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MCTA
Charming Medical Limited Class A Ordinary Shares

Medical - Care Facilities

HealthcareNASDAQ • HK
Market Cap$445M
5Y Perf.+33.2%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$4.17B
5Y Perf.+216.1%
ICHR
Ichor Holdings, Ltd.

Semiconductors

TechnologyNASDAQ • US
Market Cap$2.55B
5Y Perf.+222.1%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$272M
5Y Perf.-75.7%

MCTA vs ACMR vs ICHR vs CANG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MCTA logoMCTA
ACMR logoACMR
ICHR logoICHR
CANG logoCANG
IndustryMedical - Care FacilitiesSemiconductorsSemiconductorsAuto - Dealerships
Market Cap$445M$4.17B$2.55B$272M
Revenue (TTM)$6M$960M$959M$3.46B
Net Income (TTM)$1M$91M$-51M$-178M
Gross Margin67.2%44.2%11.3%13.6%
Operating Margin22.3%12.5%-3.8%7.3%
Forward P/E414.5x32.4x53.2x6.1x
Total Debt$1M$303M$186M$170M
Cash & Equiv.$817K$766M$98M$1.29B

MCTA vs ACMR vs ICHR vs CANGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MCTA
ACMR
ICHR
CANG
StockMay 20May 26Return
ACM Research, Inc. (ACMR)100316.1+216.1%
Ichor Holdings, Ltd. (ICHR)100322.1+222.1%
Cango Inc. (CANG)10024.3-75.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: MCTA vs ACMR vs ICHR vs CANG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCTA leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. ACM Research, Inc. is the stronger pick specifically for growth and revenue expansion and dividend income and shareholder returns. CANG also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
MCTA
Charming Medical Limited Class A Ordinary Shares
The Quality Compounder

MCTA carries the broadest edge in this set and is the clearest fit for quality and momentum.

  • 19.3% margin vs ICHR's -5.3%
  • +319.3% vs CANG's -73.2%
  • 23.4% ROA vs ICHR's -5.2%, ROIC 265.0% vs -3.9%
Best for: quality and momentum
ACMR
ACM Research, Inc.
The Growth Play

ACMR is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 15.2%, EPS growth -10.5%, 3Y rev CAGR 32.3%
  • 32.7% 10Y total return vs MCTA's 319.3%
  • Beta 3.17, yield 0.2%, current ratio 3.27x
  • 15.2% revenue growth vs CANG's -52.7%
Best for: growth exposure and long-term compounding
ICHR
Ichor Holdings, Ltd.
The Secondary Option

ICHR lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: technology exposure
CANG
Cango Inc.
The Income Pick

CANG is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 5 yrs, beta 2.49
  • Lower volatility, beta 2.49, Low D/E 4.1%, current ratio 1.88x
  • Lower P/E (6.1x vs 53.2x)
  • Beta 2.49 vs ICHR's 3.78, lower leverage
Best for: income & stability and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthACMR logoACMR15.2% revenue growth vs CANG's -52.7%
ValueCANG logoCANGLower P/E (6.1x vs 53.2x)
Quality / MarginsMCTA logoMCTA19.3% margin vs ICHR's -5.3%
Stability / SafetyCANG logoCANGBeta 2.49 vs ICHR's 3.78, lower leverage
DividendsACMR logoACMR0.2% yield; 3-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)MCTA logoMCTA+319.3% vs CANG's -73.2%
Efficiency (ROA)MCTA logoMCTA23.4% ROA vs ICHR's -5.2%, ROIC 265.0% vs -3.9%

MCTA vs ACMR vs ICHR vs CANG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MCTACharming Medical Limited Class A Ordinary Shares

Segment breakdown not available.

ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M
ICHRIchor Holdings, Ltd.

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M

MCTA vs ACMR vs ICHR vs CANG — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCTALAGGINGICHR

Income & Cash Flow (Last 12 Months)

MCTA leads this category, winning 4 of 6 comparable metrics.

CANG is the larger business by revenue, generating $3.5B annually — 556.1x MCTA's $6M. MCTA is the more profitable business, keeping 19.3% of every revenue dollar as net income compared to ICHR's -5.3%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
RevenueTrailing 12 months$6M$960M$959M$3.5B
EBITDAEarnings before interest/tax$139M-$11M$333M
Net IncomeAfter-tax profit$91M-$51M-$178M
Free Cash FlowCash after capex-$108M-$17M$0
Gross MarginGross profit ÷ Revenue+67.2%+44.2%+11.3%+13.6%
Operating MarginEBIT ÷ Revenue+22.3%+12.5%-3.8%+7.3%
Net MarginNet income ÷ Revenue+19.3%+9.5%-5.3%-5.2%
FCF MarginFCF ÷ Revenue+2.2%-11.3%-1.7%-154.0%
Rev. Growth (YoY)Latest quarter vs prior year+34.2%+4.7%+58.3%
EPS Growth (YoY)Latest quarter vs prior year-20.0%+46.2%+3.6%
MCTA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

CANG leads this category, winning 3 of 5 comparable metrics.

At 6.1x trailing earnings, CANG trades at a 99% valuation discount to MCTA's 414.5x P/E. On an enterprise value basis, CANG's 3.9x EV/EBITDA is more attractive than MCTA's 269.8x.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
Market CapShares × price$445M$4.2B$2.5B$272M
Enterprise ValueMkt cap + debt − cash$446M$3.7B$2.6B$107M
Trailing P/EPrice ÷ TTM EPS414.55x45.98x-47.58x6.14x
Forward P/EPrice ÷ next-FY EPS est.32.43x53.16x
PEG RatioP/E ÷ EPS growth rate1.30x
EV / EBITDAEnterprise value multiple269.80x29.49x3.90x
Price / SalesMarket cap ÷ Revenue71.60x4.63x2.69x2.29x
Price / BookPrice ÷ Book value/share9999.00x2.20x3.78x0.45x
Price / FCFMarket cap ÷ FCF3219.65x
CANG leads this category, winning 3 of 5 comparable metrics.

Profitability & Efficiency

MCTA leads this category, winning 7 of 9 comparable metrics.

MCTA delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-8 for ICHR. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCTA's 23.57x. On the Piotroski fundamental quality scale (0–9), MCTA scores 6/9 vs ACMR's 2/9, reflecting solid financial health.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
ROE (TTM)Return on equity+24.4%+5.1%-7.5%-4.1%
ROA (TTM)Return on assets+23.4%+3.4%-5.2%-2.3%
ROICReturn on invested capital+2.6%+7.0%-3.9%+4.6%
ROCEReturn on capital employed+3.4%+6.6%-4.7%+4.5%
Piotroski ScoreFundamental quality 0–96234
Debt / EquityFinancial leverage23.57x0.16x0.28x0.04x
Net DebtTotal debt minus cash$343,868-$463M$87M-$1.1B
Cash & Equiv.Liquid assets$816,771$766M$98M$1.3B
Total DebtShort + long-term debt$1M$303M$186M$170M
Interest CoverageEBIT ÷ Interest expense66.54x20.41x-5.97x-1.87x
MCTA leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ACMR leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCTA five years ago would be worth $41,929 today (with dividends reinvested), compared to $9,668 for CANG. Over the past 12 months, MCTA leads with a +319.3% total return vs CANG's -73.2%. The 3-year compound annual growth rate (CAGR) favors ACMR at 90.2% vs CANG's 1.3% — a key indicator of consistent wealth creation.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
YTD ReturnYear-to-date-0.0%+40.4%+259.0%-58.7%
1-Year ReturnPast 12 months+319.3%+155.8%+298.0%-73.2%
3-Year ReturnCumulative with dividends+319.3%+588.4%+168.5%+4.0%
5-Year ReturnCumulative with dividends+319.3%+194.1%+53.9%-3.3%
10-Year ReturnCumulative with dividends+319.3%+3268.4%+650.1%-44.2%
CAGR (3Y)Annualised 3-year return+61.3%+90.2%+39.0%+1.3%
ACMR leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — ICHR and CANG each lead in 1 of 2 comparable metrics.

CANG is the less volatile stock with a 2.49 beta — it tends to amplify market swings less than ICHR's 3.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ICHR currently trades 93.9% from its 52-week high vs CANG's 20.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
Beta (5Y)Sensitivity to S&P 5003.17x3.78x2.49x
52-Week HighHighest price in past year$31.70$71.65$78.00$2.88
52-Week LowLowest price in past year$4.30$21.87$13.12$0.33
% of 52W HighCurrent price vs 52-week peak+92.6%+87.9%+93.9%+20.2%
RSI (14)Momentum oscillator 0–10078.572.670.167.0
Avg Volume (50D)Average daily shares traded01.1M790K1.4M
Evenly matched — ICHR and CANG each lead in 1 of 2 comparable metrics.

Analyst Outlook

CANG leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ACMR as "Buy", ICHR as "Buy", CANG as "Buy". Consensus price targets imply 414.9% upside for CANG (target: $3) vs -25.5% for ICHR (target: $55). ACMR is the only dividend payer here at 0.18% yield — a key consideration for income-focused portfolios.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$75.00$54.60$3.00
# AnalystsCovering analysts10142
Dividend YieldAnnual dividend ÷ price+0.2%
Dividend StreakConsecutive years of raises315
Dividend / ShareAnnual DPS$0.11
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%0.0%+4.9%
CANG leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MCTA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CANG leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallCharming Medical Limited Cl… (MCTA)Leads 2 of 6 categories
Loading custom metrics...

MCTA vs ACMR vs ICHR vs CANG: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MCTA or ACMR or ICHR or CANG a better buy right now?

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MCTA or ACMR or ICHR or CANG?

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 6. 1x versus Charming Medical Limited Class A Ordinary Shares at 414. 5x. On forward P/E, ACM Research, Inc. is actually cheaper at 32. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — MCTA or ACMR or ICHR or CANG?

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to -3. 3% for Cango Inc. (CANG). Over 10 years, the gap is even starker: ACMR returned +32. 7% versus CANG's -44. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MCTA or ACMR or ICHR or CANG?

By beta (market sensitivity over 5 years), Cango Inc.

(CANG) is the lower-risk stock at 2. 49β versus Ichor Holdings, Ltd. 's 3. 78β — meaning ICHR is approximately 52% more volatile than CANG relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

05

Which is growing faster — MCTA or ACMR or ICHR or CANG?

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MCTA or ACMR or ICHR or CANG?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -5. 6% for Ichor Holdings, Ltd. — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus -4. 1% for ICHR. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MCTA or ACMR or ICHR or CANG more undervalued right now?

On forward earnings alone, ACM Research, Inc.

(ACMR) trades at 32. 4x forward P/E versus 53. 2x for Ichor Holdings, Ltd. — 20. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 414. 9% to $3. 00.

08

Which pays a better dividend — MCTA or ACMR or ICHR or CANG?

In this comparison, ACMR (0.

2% yield) pays a dividend. MCTA, ICHR, CANG do not pay a meaningful dividend and should not be held primarily for income.

09

Is MCTA or ACMR or ICHR or CANG better for a retirement portfolio?

For long-horizon retirement investors, Ichor Holdings, Ltd.

(ICHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+650. 1% 10Y return). Cango Inc. (CANG) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ICHR: +650. 1%, CANG: -44. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MCTA and ACMR and ICHR and CANG?

These companies operate in different sectors (MCTA (Healthcare) and ACMR (Technology) and ICHR (Technology) and CANG (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MCTA is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; CANG is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MCTA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen
Stocks Like

ACMR

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 17%
  • Net Margin > 5%
Run This Screen
Stocks Like

ICHR

Quality Business

  • Sector: Technology
  • Market Cap > $100B
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MCTA and ACMR and ICHR and CANG on the metrics below

Revenue Growth>
%
(MCTA: 3.4% · ACMR: 34.2%)
Net Margin>
%
(MCTA: 19.3% · ACMR: 9.5%)
P/E Ratio<
x
(MCTA: 414.5x · ACMR: 46.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.